The NASH Education Program™

Improving together the medical learning about NASH to better address its causes and consequences and serve patients
THE NASH EDUCATION PROGRAMTM: MEDICAL EDUCATION FOR BETTER CARE
NASH (non-alcoholic steatohepatitis) is a severe and widespread metabolic liver disease, yet little-known, as it is silent and asymptomatic. It is essentially the result of modern lifestyles, and is closely related to the triple epidemic of obesity, diabetes, and pre-diabetes.



NASH AFFECTS AROUND 10% OF THE ADULT POPULATION IN DEVELOPED COUNTRIES


As a recognized leader in the NASH field, GENFIT¹ has a responsibility for being proactive in NASH disease awareness. For this reason it has launched The NASH Education ProgramTM in March 2017, an independent entity with its own legal status.

The NASH Education ProgramTM defines and drives initiatives in collaboration with an independent scientific committee² composed of four international key opinion leaders, well-known and respected in the field, with a footprint in both hepatic and metabolic diseases, and a strong presence in the United States as well as in Europe.

The objective of this public health initiative is to place the practitioner and the patient at the heart of tomorrow's awareness and education actions. It aims at producing essential and relevant scientific and medical knowledge, and at disseminating it towards targeted audiences:
  • > All physician specialties, going beyond hepato-gastroenterology, i.e. including diabetologists, endocrinologists, obesity specialists, cardiologists, OB-GYN and general practitioners who will all have a key role to play in the clinical management of NASH patients;
  • > Patients and their families, but also individuals at risk, who all need to understand causes, mechanisms and consequences of the disease, to fully appreciate the importance of an early diagnosis and a treatment well-suited to their condition.
Through this approach, The NASH Education ProgramTM creates opportunities to increase awareness through relevant and impactful education actions. It is obviously open to all key stakeholders in the NASH space who are committed to improving NASH patient care.


Jean-François Mouney, President

The NASH Education ProgramTM





(1) GENFIT’s commitment to the fight against NASH materializes through its research activities, with an anti-NASH drug-candidate in phase 3 clinical study and an in vitro diagnostic test relying on blood biomarkers currently in industrial development. Additionally, the company holds a privileged status into the Liver Forum with its Chief Medical Officer acting as a member of the steering committee, and co-chair of a working group.

(2) Professor Stephen Harrison (Hepatologist, USA), Professor Kenneth Cusi (Endocrinologist, USA), Professor Sven Francque (Hepatologist, Belgium), Professor Bertrand Cariou (Endocrinologist, France).


PRESS RELEASES

Educational Video: NASH, anticipating an impending storm

CONFERENCE: UNDERSTANDING NASH & THE NEED FOR EDUCATION (FRENCH VERSION)

more information
About The NASH Education Program
NAFLD/NASH Medical Monograph
Press Conference Presentation (French version)
 Contact Us

and find out more about the Nash Education ProgramTM